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Background: Few clinical studies have focused on the efficacy of lipid-lowering therapies in patients ≥65 years.
Methods: After stabilization on atorvastatin 10 mg, hypercholesterolemic subjects ≥65 years at high/very high risk
for CHD and not at LDL-C <1.81 mmol/L (with atherosclerotic vascular disease [AVD]) or <2.59 mmol/L (without
AVD) were randomized to ezetimibe 10 mg plus atorvastatin 10 mg or uptitration to atorvastatin 20 mg (6 weeks)
followed by uptitration to 40 mg (additional 6 weeks). A post-hoc analysis compared between-group differences in
percent attainment of individual and combined LDL-C, non-HDL-C and Apo B targets based on recommendations
from 2012 European and Canadian Cardiovascular Society (CCS) guidelines for dyslipidemia treatment.
Results: Atorvastatin 10 mg plus ezetimibe produced significantly greater attainment of LDL-C, non-HDL-C, and
Apo B individual and dual/triple targets vs. atorvastatin 20 mg for the entire cohort and very high-risk groups at
6 weeks. After 12 weeks, very high-risk subjects maintained significantly greater achievement of LDL-C <1.8 mmol/L
(47% vs. 35%), non-HDL-C <2.6 mmol/L (63% vs. 53%) and Apo B <0.8 g/L (47% vs. 38%) single targets and dual/
triple targets with atorvastatin 10 mg plus ezetimibe vs. atorvastatin 40 mg, while attainment of European target for
high-risk subjects was generally similar for both treatments. Achievement of Canadian targets was significantly
greater with combination therapy vs. atorvastatin 20 mg (6 weeks) or atorvastatin 40 mg (12 weeks).
Conclusions: Atorvastatin 10 mg plus ezetimibe provided more effective treatment than uptitration to atorvastatin
20/40 mg for attainment of most European and Canadian guideline-recommended lipid targets in older at-risk patients.
Trial registration: ClinicalTrials.gov identifier NCT00418834.
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Cardiovascular disease (CVD) is a leading contributor to
global morbidity and mortality, accounting for 40% of all
deaths in the European Union and about one-third of all
deaths in Canada (~29%) [1,2]. Canadian and European
guidelines have identified low-density lipoprotein choles-
terol (LDL-C) as the primary therapeutic target for treat-
ment of patients with hypercholesterolemia and CVD or* Correspondence: constancec@videotron.ca
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article, unless otherwise stated.CVD risk factors [3,4]. The Canadian guidelines and the
European guidelines recommend apolipoprotein (Apo) B,
and non-high-density lipoprotein (HDL)-C as secondary
targets and total cholesterol is recommended as a second-
ary target by the European guidelines [3,4]. While the
Canadian guidelines specify that treatment targets should
not change based on risk assessment, the European guide-
lines designate different levels based on risk; more aggres-
sive goals are recommended for patients at very high risk
for CVD relative to those at high or moderate CVD risk
[4]. Although increasing age is a risk factor for CVD, nei-
ther set of guidelines recommends specific targets basedtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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strategies to achieve some of the more aggressive lipid-
lowering targets [5-8]. In addition, there is strong justifica-
tion for intensive LDL-C-lowering therapy in individuals
older than 65 years with established CVD [7].
Although aggressive therapy with high-dose statins has
been shown to provide clinical benefit [5], it is not always
an option in elderly patients. Concerns about tolerability
exist due to differences in metabolism, greater likelihood
of polypharmacy, and potentially greater risk of myopathy.
Combination therapy, such as the addition of ezetimibe
10 mg to atorvastatin 10 mg, may deliver complementary
effects on lipids that surpass those of atorvastatin mono-
therapy titrated to higher doses, while providing compar-
able tolerability. This post hoc analysis of data from the
ZETia in the ELDerly (ZETELD) study [9] assessed the
effects of adding ezetimibe to atorvastatin 10 mg versus
doubling the atorvastatin dose to 20 mg (first 6 weeks)
followed by uptitration to atorvastatin 40 mg for an
additional 6 weeks on the attainment of specified lipid
targets in patients ≥65 years with hypercholesterolemia,
based on recommendations for targets defined by the
2012 European and 2012 Canadian guidelines for treat-
ment of dyslipidemias [3,4].
Methods
Trial design
This post hoc analysis evaluated data from the previously
reported 12-week multicenter, randomized, double-blind,
parallel-arm ZETELD study (ClinicalTrials.gov identifier
NCT00418834; protocol number 112) [9]. The investi-
gational review boards of each participating study site
reviewed and approved the protocol and amendments,
and all subjects provided written informed consent prior
to performance of any study procedure.
Subjects and therapy
Details of the study have been previously described [9].
Briefly, participants eligible for inclusion were males and
females ≥65 years with or without atherosclerotic vascular
disease (AVD) who had not reached LDL-C target levels
of <1.81 mmol/L (those with AVD) or <2.59 mmol/L
(those without AVD) during atorvastatin 10 mg/d therapy.
Subjects were eligible for study inclusion if they met
the following criteria: established coronary heart disease
(CHD) and other AVD with LDL-C levels ≥1.81 mmol/L
and ≤4.14 mmol/L; subjects without AVD who had
diabetes mellitus (type 1 or 2), or multiple risk fac-
tors and a 10-year risk for CHD >20% (as determined
by the Framingham calculation) [10,11] and LDL-C
levels ≥2.59 mmol/L and ≤4.92 mmol/L; triglycer-
ides ≤3.96 mmol/L; alanine aminotransferase and aspar-
tate aminotransferase ≤1.5 times the upper limit of normal
(ULN) with no active liver disease; creatine kinase ≤2times the ULN; thyroid stimulating hormone ≥0.3
or ≤5.0 μIU/mL; and HbA1c <8.5%. Patients were
excluded from the study if they had uncontrolled hy-
pertension (systolic blood pressure >160 mmHg or
diastolic >100 mmHg), impaired renal function (cre-
atinine ≥2.0 mg/d or a history of nephrotic range pro-
teinuria), or were taking a lipid-lowering agent with
greater potency than atorvastatin 20 mg (acceptable
treatment included atorvastatin 10-20 mg, simvastatin
10-40 mg, pravastatin 10-40 mg, fluvastatin 20-80 mg,
lovastatin 10-40 mg, rosuvastatin 5 mg, or ezetimibe
10 mg) within 6 weeks or fibrates within 8 weeks of
screening. Subjects enrolled in the study received single-
blind atorvastatin 10 mg daily during a 4 week run-in
period. Following the run-in period, qualified patients were
randomized to receive ezetimibe and atorvastatin or ator-
vastatin alone. Randomization was stratified based on base-
line LDL-C levels and the presence or absence of AVD to
achieve balance across treatment groups (1: LDL-C ≥70
to <100 mg/dL with AVD; 2: LDL-C ≥100 to <130 mg/dL
with AVD; 3: LDL-C ≥100 to <130 mg/dL without AVD;
4: LDL-C ≥130 to ≤160 mg/dL with AVD; 5: LDL-C ≥130
to <160 without AVD; 6: LDL-C ≥160 to ≤190 without
AVD [LDL-C conversions: 70 mg/dL = 1.81 mmol/L,
100 mg/dL = 2.59 mmol/L, 130 mg/dL = 3.37 mmol/L,
160 mg/dL = 4.14 mmol/L, 190 mg/dL = 4.92 mmol/L]).
During the first 6 weeks, patients received ezetimibe 10 mg
plus atorvastatin 10 mg daily, or atorvastatin 20 mg daily.
After the first 6 weeks, subjects in the ezetimibe 10 mg
plus atorvastatin 10 mg group continued on the same
treatment for an additional 6 week period while subjects in
the atorvastatin 20 mg group were titrated to atorvastatin
40 mg for an additional 6 weeks.
Statistical methods
Consistent with the main study, this post hoc analysis
included all randomized subjects with a baseline and at
least one post-baseline evaluation. The proportion of
subjects achieving risk-based LDL-C, non-HDL-C, and
Apo B treatment targets as defined in the current
European guidelines on cardiovascular disease preven-
tion in clinical practice (version 2012) [4] and the 2012
Canadian Cardiovascular Society/Canadian guidelines
for treatment of dyslipidemia [3], were assessed after
6 weeks and after 12 weeks of treatment by logistical
regression with a term for treatment. Attainment of
individual targets, dual targets of LDL-C and either
non-HDL-C or Apo B, as well as the combination of
all three targets was evaluated for all randomized sub-
jects and for subgroups based on risk when evaluating
targets defined in the European guidelines. Statistical
significance for between-treatment differences was de-
termined using 95% confidence intervals for odds ra-
tios which excluded 1. This was a post hoc analysis.
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overall type 1 error rate is greater than 0.05. Target
levels based on Canadian guidelines included LDL-
C ≤2.0 mmol/L, non-HDL-C ≤2.6 mmol/L and Apo
B ≤0.8 g/L. Target levels based on European guidelines
included LDL-C <2.5 mmol/L, non-HDL-C <3.3 mmol/L,
and Apo B <1.0 g/L for subjects at high risk for (i.e.
those without AVD) and LDL-C <1.8 mmol/L, non-
HDL-C <2.6 mmol/L, and Apo B <0.8 g/L for subjects at
very high risk (i.e. those with AVD). Of note, dual and
triple targets are not explicitly stated in either the European
or Canadian guidelines, but were defined a priori for these
analyses. Safety and tolerability were evaluated previously
[9,12] and were not included in this post hoc analysis.
Results
Of 2276 subjects screened for this study, 1053 were
randomized; 526 to atorvastatin 10 mg plus ezetimibe
10 mg add-on, and 527 to atorvastatin 20/40 mg. Patient
discontinuation after randomization (23 receiving atorva-
statin plus ezetimibe, 20 receiving atorvastatin 20/40),
baseline demographics (including the National Cholesterol
Education Program, Adult Treatment Panel III [NCEP ATP
III] defined risk), and baseline lipid values were similar
between treatment groups and previously described [9].
Overall, the mean age was 71 years (±5), 53% were women,
96% were white, approximately 30% were obese (body
mass index ≥30 kg/m2), ≥80% had CHD or AVD, and the
mean treated baseline LDL-C levels ranged from 2.62 and
2.67 mmol/L. Baseline lipid levels along with recommended
lipid targets from the European and Canadian guidelines
are shown in Table 1. Baseline lipids were generally similar
between treatment groups and subgroups by AVD status.
Efficacy endpoints
The proportion of subjects achieving targets defined by
the 2012 Canadian guidelines for LDL-C, non-HDL-C,Table 1 Current European and Canadian guideline recommen
study participants
Parameter Subjects without AVD
Guidelines Treatment gro
CCS* EU† high risk E + A10 A
n = 66‡ n =
LDL-C (mmol/L) ≤2.0 or <2.5 3.25 (0.55) 3.11
↓50%
Non-HDL-C (mmol/L) ≤2.6 <3.3 4.04 (0.64) 3.84
Apo B (g/L) ≤0.8 <1.0 1.2 (0.2) 1.1
Baseline lipid and lipoprotein levels were determined for parameters common to C
A 10/20, atorvastatin 10 or 20 mg; Apo, apolipoprotein; AVD, atherosclerotic vascular d
10 mg; EU, European Guidelines (2012); LDL-C, low-density lipoprotein cholesterol; non
*Canadian guidelines specify that treatment targets should not change based on ri
†European guidelines state that total cholesterol should be considered a treatment
‡n may vary slightly between measured parameters due to differences in availableand Apo B are shown in Figure 1. At 6 weeks, the per-
centage of subjects with LDL-C ≤2.0 mmol/L was 62.3%
with ezetimibe add-on to atorvastatin 10 mg compared
with 31.1% with atorvastatin titration to 20 mg. A greater
proportion of subjects also attained the single targets of
non-HDL-C ≤2.6 mmol/L and Apo B ≤0.8 g/L, as well as
dual and triple combination targets with ezetimibe plus
atorvastatin combination therapy. The odds ratios were sig-
nificant for all comparisons (Table 2). After an additional
6 weeks, subjects continuing on ezetimibe plus atorvastatin
10 mg maintained a similar level of attainment for single,
dual, and triple targets, while percent attainment of targets
for subjects titrated from atorvastatin 20 mg to atorvastatin
40 mg showed an approximately 19 percentage point in-
crease in LDL-C target attainment, 14 percentage point in-
crease in non-HDL-C target attainment, 7 percentage point
increase in Apo B target attainment, and a 14-19 percent-
age point increase in dual/triple target attainment. The
proportion of subjects reaching single, dual, or triple
targets at 12 weeks was greater for ezetimibe add-on
therapy (Table 2).
Target levels for LDL-C <2.5 mmol/L, non-HDL-
C <3.3 mmol/L, and Apo B <1.0 g/L for subjects at high
risk were evaluated based on recommendations from the
European Guidelines as single, dual, and triple target com-
binations for the entire patient population as well as for
subjects at high risk without AVD (Figure 2). When all
subjects were included in the analysis, after 6 weeks of
therapy attainment of single, dual, and triple target combi-
nations was achieved by a greater proportion of subjects
receiving ezetimibe add-on to atorvastatin 10 mg com-
pared with subjects titrated to atorvastatin 20 mg (Table 2).
At 12 weeks, attainment was numerically higher with eze-
timibe plus atorvastatin compared with up titration to
atorvastatin 40 mg for all targets, but the odds ratios were
only significant for LDL-C <2.5 mmol/L alone or for the
dual target of LDL-C <2.5 mmol/L and non-HDL-Cdations for lipids, lipoproteins, and baseline levels for
Subjects with AVD
up Guidelines Treatment group
20 CCS* EU† very high risk E + A10 A20
67‡ n = 449‡ n = 448‡
(0.53) ≤2.0 or <1.8 2.58 (0.70) 2.56 (0.49)
↓50% or ↓50%
(0.65) ≤2.6 <2.6 3.21 (0.76) 3.21 (0.61)
(0.2) ≤0.8 <0.8 1.0 (0.2) 1.0 (0.2)
CS2012 and EU2012 targets.
isease; CCS, Canadian Cardiovascular Society guidelines (2012); E, ezetimibe
-HDL-C, non-high-density lipoprotein cholesterol.
sk assessment.
target if other analyses are not available.
data.
Figure 1 Proportion of subjects achieving targets defined by Canadian guidelines*. Error bars = standard error. *Canadian Cardiovascular
Society/Canadian Dyslipidemia guidelines (2012) [4]. † Triple combination includes LDL-C ≤2.0 mmol/L, non-HDL-C ≤2.6 mmol/L, and Apo B≤0.8 g/L.
A, atorvastatin (10, 20 or 40 mg); Apo, apolipoprotein; AVD, atherosclerotic vascular disease; E, ezetimibe 10 mg; LDL-C, low-density lipoprotein
cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol.
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attainment of single, dual, and triple targets after 6 weeks
of treatment were numerically greater with ezetimibe plus
atorvastatin 10 mg than atorvastatin 20 mg, with predictive
odds that were significant only for LDL-C <2.5 mg/dL.
After 12 weeks, the proportion of subjects achieving each
of the target levels was similar between treatments. The
level of target attainment by subjects at high risk without
AVD was approximately 15-20 percentage points lower
than that for the entire patient population.
European guideline targets defined for subjects with
very high risk include LDL-C <1.8 mmol/L, non-HDL-C
<2.6 mmol/L, and Apo B <0.8 g/L; achievement of these
levels as single, dual, and triple target combinations were
evaluated for all subjects and for subjects at very high risk
with AVD (Figure 3). After 6 weeks of treatment for the
entire study cohort, achievement of all target levels was ap-
proximately 1.5 to 3 times higher with ezetimibe add-on to
atorvastatin 10 mg than with atorvastatin 20 mg. These dif-
ferences were statistically significant (Table 2). At 12 weeks,
the level of attainment was maintained for ezetimibe plus
atorvastatin and increased by 7-15 percentage points after
titration to atorvastatin 40 mg, with all odds ratios signifi-
cantly in favor of combined therapy. Attainment levels of
single, dual, and triple targets for subjects at very high risk
with AVD were similar to that observed for the full study
cohort, with all odds ratios being significant after 6 weeks
(range from 2.15 to 4.52) and 12 weeks (range from 1.46
to 1.68) of therapy.
Discussion
Epidemiological studies have identified several risk factors
for CVD. These include both non-modifiable factors such
as age, family history, and male sex; and modifiable factors,
such as smoking, blood pressure, and cholesterol levels.
The identification and management of these modifiablerisk factors is an important step for reducing the risk of
CVD and cardiovascular events in patients at any age.
Treatment with more intensive statin doses has been
shown to have significantly greater effects than moderate
statin therapy on cholesterol reduction in the general
population [13]; and the use of intensive lipid-altering
therapy is supported in older subjects as well [5,6]. A re-
cent observational study of clinical practice in Europe
and Canada highlights the need for better management
of dyslipidemia, with almost half of the 22,063 statin-
treated patients studied (mean age of 65.7 ± 9.9 years)
having LDL-C levels above guideline recommended
targets [13].
The present post hoc analysis showed that in subjects
aged 65 years and older, the odds of achieving the LDL-C,
non-HDL-C and Apo B treatment targets recommended
by the 2012 Canadian and 2012 European treatment guide-
lines were greater with the combination of atorvastatin
10 mg plus ezetimibe 10 mg compared with uptitration
of atorvastatin to 20 mg for 6 weeks and 40 mg for an
additional 6 weeks. Moreover, in the subgroup of sub-
jects at very high risk, the odds of achieving the most
aggressive lipid targets were greater with the combi-
nation compared with uptitration at both 6 weeks and
12 weeks, similar to the odds of target achievement in
the overall population. In the subgroup of subjects at high
risk; however, the odds of achieving most of the recom-
mended targets were similar for both treatments at both
6 weeks and 12 weeks. These results were consistent with
the primary analysis which evaluated the attainment of
LDL-C <70 mg/dL or LDL-C <100 or <70 mg/dL for all
subjects.
It has been suggested that statin therapy should be
used more conservatively in older patients, especially in
those with an increased susceptibility to adverse events
due to concomitant illnesses and/or medications [14].
Table 2 Percent achievement and odds ratios for LDL-C, non-HDL-C and Apo B targets
All subjects High risk or very high risk subjects
Week 6 Week 12 Week 6 Week 12
Targets E + A10 A20 OR E + A10 A20/A40 OR E + A10 A20 OR E + A10 A20/A40 OR
(mmol/L) for LDL-C, non-HDL-C; g/L for Apo B
Canadian (N = 515) (N = 515) (N = 516) (N = 509)
Single
LDL-C≤2.0 62.3 31.1 3.67* 60.5 49.7 1.55*
non-HDL-C≤2.6 62.3 35.9 2.95* 58.5 49.7 1.43*
Apo B ≤0.8 47.7 31.1 2.02* 44.6 38.1 1.31*
Dual/Triple
LDL-C≤2.0, non-HDL-C≤2.6 57.1 25.4 3.90* 53.1 44.2 1.43*
LDL-C≤2.0, Apo B ≤1.0 45.2 21.6 2.99* 41.7 35.2 1.32*
LDL-C≤2.0, non-HDL≤2.6, Apo B≤0.8 44.8 20.6 3.12* 41.3 34.8 1.32*
EU-High Risk (N = 515) (N = 515) (N = 516) (N = 516) (n = 66) (n = 67) (n = 67) (n = 67)
Single
LDL-C <2.5 85.2 72.6 2.18* 82.4 77.0 1.39* 68.2 50.7 2.08* 61.2 61.2 1.00
non-HDL-C <3.3 86.2 78.1 1.76* 84.1 81.9 1.17 68.2 59.7 1.45 68.7 70.1 0.93
Apo B <1.0 78.3 69.5 1.59* 74.8 71.5 1.18 58.7 48.5 1.51 53.8 53.0 1.03
Dual/Triple
LDL-C <2.5, non-HDL-C <3.3 83.9 70.3 2.20* 81.0 74.3 1.48* 66.7 50.7 1.94 61.2 58.2 1.13
LDL-C <2.5, Apo B <1.0 76.3 63.6 1.84* 72.8 67.8 1.27 55.6 40.9 1.81 49.2 50.0 0.97
LDL-C <2.5, non-HDL <3.3, Apo B <1.0 75.9 63.0 1.85* 72.6 67.2 1.29 55.6 40.9 1.81 49.2 50.0 0.97
EU-Very High Risk (N = 515) (N = 515) (N = 516) (N = 516) (n = 449) (n = 448) (n = 449) (n = 442)
Single
LDL-C <1.8 47.4 17.9 4.14* 43.6 32.2 1.63* 50.8 20.1 4.10* 47.2 35.3 1.64*
Non-HDL-C <2.6 62.3 35.9 2.95* 58.5 49.7 1.43* 66.1 39.7 2.96* 62.6 52.5 1.51*
Apo B <0.8 45.4 28.0 2.13* 43.8 35.4 1.43* 48.9 30.8 2.15* 46.9 37.7 1.46*
Dual/Triple
LDL-C <1.8, non-HDL-C <2.6 45.4 15.1 46.7* 41.3 30.1 1.64* 48.8 17.4 4.52* 45.0 32.8 1.68*
LDL-C <1.8, Apo B <0.8 38.7 14.4 3.75* 35.2 25.9 1.56* 41.4 16.3 3.64* 38.1 28.2 1.57*
LDL-C <1.8, non-HDL <2.6, Apo B <0.8 38.3 13.6 3.93* 35.2 25.7 1.57* 41.0 15.6 3.75* 38.1 28.0 1.59*
N may vary slightly between measured parameters due to differences in available data.
*OR considered significant based on associated 95% confidence interval which excludes 1.
A 10/20, atorvastatin 10 or 20 mg; Apo, apolipoprotein; AVD, atherosclerotic vascular disease; Canadian, Canadian Cardiovascular Society guidelines (2012); E, ezetimibe 10 mg; EU, European Guidelines (2012); LDL-C,






















Figure 2 Proportion of all and high-risk subjects achieving targets defined by European guidelines*. A. All Subjects. B. High-Risk Subjects without
AVD. Error bars = standard error. * European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) [12]. † Triple combination
includes LDL-C <2.5 mmol/L, non-HDL-C <3.3 mmol/L, and Apo B <1.0 g/L. A, atorvastatin (10, 20 or 40 mg); Apo, apolipoprotein; AVD, atherosclerotic
vascular disease; E, ezetimibe 10 mg; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol.
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demonstrated greater benefits of intensive versus moderate
statin therapy, suggesting that the benefits may outweigh
the concerns, caution is advised when prescribing statins
in individuals older than 65 years due to increased risk of
myopathy. The United States Food and Drug Administra-
tion has restricted the use of the 80 mg dose of simvastatin
in populations at any age [15-17]. Combination therapy
with drugs that have different mechanisms of action may
be beneficial for lipid-lowering in older patients. A pooled
analysis that included 16 studies showed that ezetimibe
used in combination with a statin lowered LDL-C 17%
more than statin monotherapy at equivalent doses in
those aged under 65, 65-74 and 75 years and older
[18]. In addition, the proportion of subjects achieving
LDL-C <100 mg/dL or <70 mg/dL was greater with the
combination therapy versus statin monotherapy in all age
groups [18]. The current analyses are consistent with these
previous reports, suggesting that therapy with ezetimibe
added to moderate doses of atorvastatin may provide a
valuable lipid-lowering option for older men and women at
high and very high risk for CVD. Of note, whether LDL-Creductions attributed to combination treatment versus sta-
tin monotherapy will result in better CVD outcomes is not
yet known and awaits results from an ongoing clinical trial.
Study limitations
Compared with the overall population and the very high
risk subgroup, which had similar group sizes to each
other, the high risk subgroup in this analysis was rela-
tively small and underpowered to show statistical signifi-
cance based on associated 95% confidence intervals.
While odds ratios for the high risk subjects were generally
consistent with the odds ratios for the overall population,
limited sample size prohibits making definitive statements
concerning the significance of these differences. The results
of these analyses were based on a study of relatively short
duration in a population that was predominantly white
(96%), which limits the ability to generalize the conclusions
to longer-term therapy and diverse populations. Of note,
the guidelines also include a 50% LDL-C reduction; but we
could not assess this as we did not have baseline naïve
LDL-C levels. Finally, these were post hoc analyses; no in-
ferential statistics were provided and no adjustments for
Figure 3 Proportion of all and very high-risk subjects achieving targets defined by European guidelines*. A. All Subjects. B. Very High-Risk
Subjects with AVD. Error bars = standard error. * European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) [12]. † Triple
combination includes LDL-C <1.8 mmol/L, non-HDL-C <2.6 mmol/L, and Apo B <0.8 g/L. A, atorvastatin (10, 20 or 40 mg); Apo, apolipoprotein; AVD,
atherosclerotic vascular disease; E, ezetimibe 10 mg; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol.
Constance et al. Lipids in Health and Disease 2014, 13:13 Page 7 of 8
http://www.lipidworld.com/content/13/1/13multiplicity were made. Therefore, although the results pro-
vide information about the efficacy of ezetimibe combined
with atorvastatin in older subjects, they should be inter-
preted with discretion.Conclusions
These results taken together with the primary findings
of the ZETELD study suggest that ezetimibe 10 mg com-
bined with atorvastatin 10 mg may provide an effective
treatment option for the management of dyslipidemia
and attainment of European and Canadian guideline-
recommended targets in patients ages 65 years and older
at high and very high risk, with comparable tolerability
to higher dose atorvastatin.Abbreviations
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